Molecular and Cellular Biochemistry

, Volume 444, Issue 1–2, pp 169–178 | Cite as

MiR-519d-3p suppresses breast cancer cell growth and motility via targeting LIM domain kinase 1

  • Dengfeng Li
  • Hongming Song
  • Tianqi Wu
  • Dan Xie
  • Jiashu Hu
  • Junyong Zhao
  • Qiang Shen
  • Lin Fang


Breast cancer is the most common female cancer in women, and its estrogen receptor (ER)-negative subtype (ENBC) and triple-negative subtype (TNBC) have unfavorable prognosis in comparison with ER-positive subtype. MiRNAs are small noncoding RNAs that bind to the 3′-UTR region of targeting mRNAs to regulate gene expression. Mir-519d-3p was found to be associated with breast cancer for its potential role in proliferation and metastasis. To explore its potential role and mechanism of miR-519d-3p in breast carcinogenesis, we determined whether miR-519d-3p regulates breast cancer cell proliferation and motility by performing wound-healing assays and migration–invasion assays. We found that miR-519d-3p significantly inhibits proliferation and motility of ENBC and TNBC cells. Overexpression of miR-519d-3p arrested breast cancer cells in the G0/G1 phase and reduced the expression of CDK4, 6/Cyclin D1, and CDK2/Cyclin E1. It was reported that miR-519d-3p or miR-519d-3p expression was associated with cancer metastasis and clinical staging. Since LIM domain kinase 1 (LIMK1) was highly expressed in breast cancer and a major regulator of breast cancer growth and metastasis, we further demonstrated that LIMK1 is a potential target of miR-519d-3p by dual-luciferase report assay. Mir-519d-3p decreases LIMK1 expression at mRNA and protein levels, and the protein level and phosphorylation of cofilin 1 (CFL1), one of the key downstream targets of LIMK1. Our findings suggest that miR-519d-3p regulates the LIMK1/CFL1 pathway in breast cancer and this new venue could be targeted for future breast cancer therapy.


MiR-519d-3p Breast cancer Proliferation Metastasis LIM domain kinase 1 Cofilin 1 



This work was supported by the Shanghai Municipal Health Bureau of Shanghai, China through Grant No. 201640097 (to L. Fang), the National Natural Science Foundation of China through Grant No. 82172240 (to L. Fang), Cancer Center Support Grant P30 CA016672 from the United States National Institutes of Health (to The University of Texas MD Anderson Cancer Center), startup funds from MD Anderson Cancer Center (to Q. Shen), and the Duncan Family Institute Seed Funding Research Program (to Q. Shen).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE (2014) Breast cancer in China. Lancet Oncol 15:e279–e289. CrossRefPubMedGoogle Scholar
  2. 2.
    Society AC (2017) Cancer facts and figs. 2017. American Cancer Society, AtlantaGoogle Scholar
  3. 3.
    Zhu J, Zhou Q, Tan S (2016) Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer. Cancer Lett 383:154–160. CrossRefPubMedGoogle Scholar
  4. 4.
    Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefPubMedGoogle Scholar
  5. 5.
    Cuberos H, Vallee B, Vourc’h P, Tastet J, Andres CR, Benedetti H (2015) Roles of LIM kinases in central nervous system function and dysfunction. FEBS Lett 589:3795–3806. CrossRefPubMedGoogle Scholar
  6. 6.
    Liao Q, Li R, Zhou R, Pan Z, Xu L, Ding Y, Zhao L (2017) LIM kinase 1 interacts with myosin-9 and alpha-actinin-4 and promotes colorectal cancer progression. Br J Cancer 117:563–571. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Park GB, Kim D (2017) PI3K catalytic isoform alteration promotes the LIMK1-related metastasis through the PAK1 or ROCK1/2 activation in cigarette smoke-exposed ovarian cancer cells. Anticancer Res 37:1805–1818. CrossRefPubMedGoogle Scholar
  8. 8.
    Li R, Doherty J, Antonipillai J, Chen S, Devlin M, Visser K, Baell J, Street I, Anderson RL, Bernard O (2013) LIM kinase inhibition reduces breast cancer growth and invasiveness but systemic inhibition does not reduce metastasis in mice. Clin Exp Metastasis 30:483–495. CrossRefPubMedGoogle Scholar
  9. 9.
    McConnell BV, Koto K, Gutierrez-Hartmann A (2011) Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Mol Cancer 10:75. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ohashi K, Sampei K, Nakagawa M, Uchiumi N, Amanuma T, Aiba S, Oikawa M, Mizuno K (2014) Damnacanthal, an effective inhibitor of LIM-kinase, inhibits cell migration and invasion. Mol Biol Cell 25:828–840. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Xiong Y, Zhang L, Kebebew E (2014) MiR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS ONE 9:e96103. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhou J, Liu R, Luo C, Zhou X, Xia K, Chen X, Zhou M, Zou Q, Cao P, Cao K (2014) MiR-20a inhibits cutaneous squamous cell carcinoma metastasis and proliferation by directly targeting LIMK1. Cancer Biol Ther 15:1340–1349. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chen P, Zeng M, Zhao Y, Fang X (2014) Upregulation of Limk1 caused by microRNA-138 loss aggravates the metastasis of ovarian cancer by activation of Limk1/cofilin signaling. Oncol Rep 32:2070–2076. CrossRefPubMedGoogle Scholar
  14. 14.
    Tan Y, Hu H, Tan W, Jin L, Liu J, Zhou H (2016) MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1. Mol Med Rep 14:4422–4428. CrossRefPubMedGoogle Scholar
  15. 15.
    Li D, Hu J, Song H, Xu H, Wu C, Zhao B, Xie D, Wu T, Zhao J, Fang L (2017) miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. Am J Transl Res 9:2276–2285PubMedPubMedCentralGoogle Scholar
  16. 16.
    Li D, Wang H, Song H, Xu H, Zhao B, Wu C, Hu J, Wu T, Xie D, Zhao J, Shen Q, Fang L (2017) The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells. Oncotarget. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang J, Kong X, Li J, Luo Q, Li X, Shen L, Chen L, Fang L (2014) miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer. Oncol Rep 31:1357–1363. CrossRefPubMedGoogle Scholar
  18. 18.
    Jacob A, Prekeris R (2015) The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol 3:4. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Goodlad RA (2017) Quantification of epithelial cell proliferation, cell dynamics, and cell kinetics in vivo. Wiley Interdiscip Rev Dev Biol. PubMedCrossRefGoogle Scholar
  20. 20.
    Deng X, Zhao Y, Wang B (2015) miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression. Oncol Rep 34:2188–2194. CrossRefPubMedGoogle Scholar
  21. 21.
    Xie Q, Wang S, Zhao Y, Zhang Z, Qin C, Yang X (2017) MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1. Oncotarget 8:22003–22013. PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Lagoutte E, Villeneuve C, Lafanechere L, Wells CM, Jones GE, Chavrier P, Rosse C (2016) LIMK regulates tumor-cell invasion and matrix degradation through tyrosine phosphorylation of MT1-MMP. Sci Rep 6:24925. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mardilovich K, Baugh M, Crighton D, Kowalczyk D, Gabrielsen M, Munro J, Croft DR, Lourenco F, James D, Kalna G, McGarry L, Rath O, Shanks E, Garnett MJ, McDermott U, Brookfield J, Charles M, Hammonds T, Olson MF (2015) LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. Oncotarget 6:38469–38486. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kang CG, Im E, Lee HJ, Lee EO (2017) Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice. Bioorg Med Chem Lett 27:1914–1918. CrossRefPubMedGoogle Scholar
  25. 25.
    Kapur R, Shi J, Ghosh J, Munugalavadla V, Sims E, Martin H, Wei L, Mali RS (2016) ROCK1 via LIM kinase regulates growth, maturation and actin based functions in mast cells. Oncotarget 7:16936–16947. PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, Aldahmash A, Alajez NM (2017) Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis 8:e3045. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Martinelli R, Nardelli C, Pilone V, Buonomo T, Liguori R, Castano I, Buono P, Masone S, Persico G, Forestieri P, Pastore L, Sacchetti L (2010) miR-519d overexpression is associated with human obesity. Obesity (Silver Spring) 18:2170–2176. CrossRefGoogle Scholar
  28. 28.
    Yue H, Tang B, Zhao Y, Niu Y, Yin P, Yang W, Zhang Z, Yu P (2017) MIR-519d suppresses the gastric cancer epithelial-mesenchymal transition via Twist1 and inhibits Wnt/beta-catenin signaling pathway. Am J Transl Res 9:3654–3664PubMedPubMedCentralGoogle Scholar
  29. 29.
    Yang X, Hu Y, Liu Y, Liu W, Zhao X, Liu M, Tang H (2017) C14orf28 downregulated by miR-519d contributes to oncogenicity and regulates apoptosis and EMT in colorectal cancer. Mol Cell Biochem. CrossRefPubMedGoogle Scholar
  30. 30.
    Zhou JY, Zheng SR, Liu J, Shi R, Yu HL, Wei M (2016) MiR-519d facilitates the progression and metastasis of cervical cancer through direct targeting Smad7. Cancer Cell Int 16:21. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Nassar FJ, Nasr R, Talhouk R (2017) MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther 172:34–49. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Division of General Surgery, Department of Thyroid and Breast, Shanghai Tenth People’s HospitalTongji University School of MedicineShanghaiPeople’s Republic of China
  2. 2.Division of Cancer Prevention and Population Science, Department of Clinical Cancer PreventionThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations